Pharmadrug Inc.
PHRX
CNSX
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -55.17% | -64.71% | -91.31% | -103.15% | -69.27% |
| Depreciation & Amortization | -1.09% | -1.09% | -5.38% | -53.37% | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -47.44% | 752.94% | -90.15% | -87.77% | -72.17% |
| Operating Income | 47.44% | -752.94% | 90.15% | 87.77% | 72.17% |
| Income Before Tax | 52.30% | 41.73% | 79.67% | 99.95% | 40.68% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 52.30% | 41.73% | 79.67% | 99.94% | 40.68% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 1.41% | -7.37% | -63.91% | 27.17% | -- |
| Net Income | 55.41% | 45.20% | 81.06% | 100.58% | 43.85% |
| EBIT | 47.44% | -752.94% | 90.15% | 87.77% | 72.17% |
| EBITDA | 62.72% | -172.00% | 92.62% | 89.38% | 78.72% |
| EPS Basic | 58.33% | 50.00% | 84.62% | 100.41% | 72.73% |
| Normalized Basic EPS | 57.14% | 50.00% | 82.61% | 102.00% | 66.67% |
| EPS Diluted | 58.33% | 50.00% | 84.62% | 100.41% | 72.73% |
| Normalized Diluted EPS | 57.14% | 50.00% | 82.61% | 102.00% | 66.67% |
| Average Basic Shares Outstanding | 3.93% | 7.82% | 13.54% | 46.54% | 104.99% |
| Average Diluted Shares Outstanding | 3.93% | 7.82% | 13.54% | 46.54% | 104.99% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |